Jedd D Wolchok
Overview
Explore the profile of Jedd D Wolchok including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
434
Citations
88887
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sethna Z, Guasp P, Reiche C, Milighetti M, Ceglia N, Patterson E, et al.
Nature
. 2025 Feb;
PMID: 39972124
A fundamental challenge for cancer vaccines is to generate long-lived functional T cells that are specific for tumour antigens. Here we find that mRNA-lipoplex vaccines against somatic mutation-derived neoantigens may...
2.
Abate M, Stroobant E, Fei T, Lin Y, Shimada S, Drebin H, et al.
Cancer Immunol Res
. 2025 Jan;
PMID: 39786344
The immune composition of solid tumors is typically inferred from biomarkers, such as histologic and molecular classifications, somatic mutational burden, and PD-L1 expression. However, the extent to which these biomarkers...
3.
Kudelka M, Richards A, Friedlander P, Wolchok J, Moy A, Shoushtari A
J Immunother Cancer
. 2024 Nov;
12(11).
PMID: 39551602
Melanoma arising in association with a blue nevus (BN) is rare but has molecular similarities to uveal melanoma (UM), including GNAQ/11 mutations. Tebentafusp was recently approved for UM based on...
4.
Marasco M, Kumar D, Seale T, Borrego S, Kaplun E, Aricescu I, et al.
Cell Rep Med
. 2024 Nov;
5(11):101818.
PMID: 39488215
Neurofibromin (NF1) is a negative regulator of RAS signaling, frequently mutated in cancer. NF1-mutant melanoma is a highly malignant tumor for which targeted therapies are lacking. Here, we use biochemical...
5.
Hackett C, Hirschhorn D, Tang M, Purdon T, Marouf Y, Piersigilli A, et al.
Mol Ther Oncol
. 2024 Sep;
32(3):200862.
PMID: 39308793
Despite therapeutic efficacy observed with immune checkpoint blockade in advanced melanoma, many tumors do not respond to treatment, representing a need for new therapies. Here, we have generated chimeric antigen...
6.
Wolchok J, Chiarion-Sileni V, Rutkowski P, Cowey C, Schadendorf D, Wagstaff J, et al.
N Engl J Med
. 2024 Sep;
392(1):11-22.
PMID: 39282897
Background: Previous results from this trial showed longer overall survival after treatment with nivolumab plus ipilimumab or with nivolumab monotherapy than with ipilimumab monotherapy in patients with advanced melanoma. Given...
7.
Verma S, Budhu S, Serganova I, Dong L, Mangarin L, Khan J, et al.
J Clin Invest
. 2024 Sep;
134(17).
PMID: 39225102
Tumor reliance on glycolysis is a hallmark of cancer. Immunotherapy is more effective in controlling glycolysis-low tumors lacking lactate dehydrogenase (LDH) due to reduced tumor lactate efflux and enhanced glucose...
8.
Lochrin S, Buonocore D, Young R, Kaley T, Postow M, Wolchok J, et al.
Pigment Cell Melanoma Res
. 2024 Jul;
37(6):801-807.
PMID: 38960393
Leptomeningeal disease (LMD) is a devastating complication of melanoma with a dismal prognosis. We present the case of a young man with stage IV BRAF V600E mutant melanoma with lung,...
9.
Budhu S, Kim K, Yip W, La Rosa S, Jebiwott S, Cai L, et al.
Front Oncol
. 2024 Jul;
14:1405486.
PMID: 38957315
Introduction: Immunotherapy is revolutionizing the management of multiple cancer types. However, only a subset of patients responds to immunotherapy. One mechanism of resistance is the absence of immune infiltrates within...
10.
Dong L, Choi H, Budhu S, Schulze I, Verma S, Mangarin L, et al.
Cancer Immunol Res
. 2024 Jun;
12(10):1392-1408.
PMID: 38885362
MEK inhibitors (MEKi) have shown limited success as a treatment for MAPK/ERK pathway-dependent cancers due to various resistance mechanisms tumor cells can employ. CH5126766 (CKI27) is an inhibitor that binds...